MeiraGTx Holdings plc develops clinical-stage genetic medicines for diseases with high unmet need, with recurring updates centered on AAV gene therapy programs, ocular disease, radiation-induced xerostomia, and regulated gene-expression technology. Company news includes clinical disclosures for AAV-hAQP1 and AAV2-hAQP1 in grade 2/3 radiation-induced xerostomia, ophthalmology programs such as AAV-AIPL1 for Leber congenital amaurosis 4, and the acquired bota-vec program for X-linked retinitis pigmentosa.
Updates also cover strategic collaborations and license agreements, in-house manufacturing capabilities for genetic medicines, riboswitch platform development, operating results, financing arrangements, shareholder voting matters, and capital-structure disclosures tied to MGTX ordinary shares.
MeiraGTx (Nasdaq: MGTX) agreed to acquire botaretigene sparoparvovec (bota-vec) from Johnson & Johnson for X-linked retinitis pigmentosa (XLRP), paying a $25 million upfront cash payment plus a one-time U.S. regulatory/commercial milestone and a high double-digit global royalty starting mid-2029.
The company completed CMC PPQ, holds commercial manufacturing licenses, has several hundred vials ready, and intends to file BLA/MAA in the U.S., EU and Japan aiming for a potential 2027 launch. Phase 3 LUMEOS showed strong secondary endpoints and functional vision gains despite the primary maze endpoint not meeting significance.
MeiraGTx (NASDAQ: MGTX) reported positive three-year data from the completed Phase 1 AQUAx study of AAV-hAQP1 for grade 2/3 late radiation-induced xerostomia on April 16, 2026. The full 36-month dataset shows PRO XQ symptom improvements and unstimulated whole saliva flow increases maintained through three years, with AAV-hAQP1 described as safe and well tolerated across doses. Management highlighted one-time in-office dosing, durability of responses, and plans for a data presentation webcast on April 16, 2026.
MeiraGTx (NASDAQ: MGTX) will present 3-year data from the open-label Phase 1 AQUAx study of AAV-hAQP1 for treatment of persistent grade 2/3 radiation-induced xerostomia on April 16, 2026 at 8:00 a.m. ET.
The presentation includes cohort-level and individual patient data for PRO Xerostomia Questionnaire (XQ) and objective Unstimulated Whole Saliva Flow Rate (UWSFR) out to three years for bilateral and unilateral cohorts, an investigator discussion of disease burden and treatment administration, commercial opportunity commentary, and a Q&A. A live webcast and replay will be available on the company investor website.
MeiraGTx (Nasdaq: MGTX) announced FDA Breakthrough Therapy Designation for AAV2-hAQP1 to treat Grade 2–3 radiation-induced xerostomia, aligned Phase 2 AQUAx2 endpoints to support a potential BLA in H1 2027 and targeted US launch in early 2028. The company reported year-end cash of $68.2M, license revenue of $75M from Lilly, and a 2025 net loss of $114.2M (−$1.42/share).
Strategic deals include a $200M upfront Hologen joint venture payment, a $75M Lilly upfront, plus potential milestones and manufacturing agreements with J&J for bota-vec.
ZipBio and MeiraGTx (Nasdaq: MGTX) signed an exclusive license agreement to advance ZipBio's first-in-class AAV gene therapy programs for Geographic Atrophy targeting the complement pathway. The deal grants MeiraGTx exclusive rights and includes upfront plus potential milestone and royalty payments; financial terms were not disclosed. The collaboration pairs ZipBio's COMPACT™ AI-designed protein therapeutics with MeiraGTx's vector design, clinical development, and in-house manufacturing capabilities, while ZipBio focuses its internal efforts on immunology and cardiovascular programs.
Graviton Bioscience (NASDAQ:MGTX) will present selective ROCK2 obesity data at the 8th Annual Evercore HealthCONx Conference on December 2, 2025 at 8:45 AM ET. CEO Samuel Waksal will lead a fireside chat covering Graviton's obesity program and its selective ROCK2 inhibitor, GV101.
Key points to be discussed include:
- Target biology: ROCK2 roles in fibrosis, inflammation, cytoskeletal mechanics, and adipose tissue.
- Preclinical efficacy: GV101 reduced lipid droplets in mouse and human adipocytes and produced weight loss in rodent models with lean mass preservation.
- Clinical significance: GV101 appears to sustain fat loss while preserving muscle.
The presentation will be webcast and open to media, investors, and the public.
MeiraGTx (Nasdaq: MGTX) reported Q3 2025 results and operational updates on Nov 13, 2025. Key corporate actions include a broad ophthalmology collaboration with Eli Lilly (upfront $75.0M; >$400M in potential milestones; tiered royalties) and progress on a joint venture with Hologen (received $50.0M of $200.0M; MeiraGTx to hold 30% of JV).
Clinical/regulatory highlights: RMAT designations for AAV2-hAQP1 and AAV-GAD, AQUAx2 pivotal enrollment on track to finish end-2025 with potential BLA pathway in early 2027, and Specials program dosing for BBS10 (RPDD).
Cash: $17.1M at Sept 30, 2025; service revenue fell to $0.4M for Q3 2025 from $10.9M year-ago.
MeiraGTx (Nasdaq: MGTX) announced a broad strategic collaboration with Eli Lilly on Nov 10, 2025 to develop and commercialize genetic medicines in ophthalmology.
MeiraGTx granted Lilly worldwide exclusive rights to its AAV-AIPL1 program for LCA4 and exclusive access to in‑house intravitreal capsids, bespoke promoters (including AI‑generated promoters), and certain riboswitch technology for ocular gene editing. Clinical data reported that 11 children born legally blind gained vision after AAV-AIPL1, with additional developmental benefits described.
Financial terms include a $75 million upfront payment, eligibility for over $400 million in milestones, and tiered royalties on licensed products.
MeiraGTx (Nasdaq: MGTX) will present two posters at the ESGCT 2025 Annual Congress in Seville, Oct 7-10, 2025.
Poster P0089 reports directed evolution of novel AAV capsids from a ~1E7-variant library in non-human primate eyes, validated in human retinal organoids and iPSC-derived RPE. Selected capsids showed >2-fold higher transduction versus AAV2.7m8 and higher retinal expression in mouse intravitreal studies, supporting ocular gene therapy applications.
Poster P0170 describes scale-up of a perfusion-based AAV manufacturing process to 40L bioreactors. Bench optimization delivered up to +120% volumetric VG yield, ~50% lower plasmid use, and up to 2.2-fold lower cost-of-goods per dose; the work focuses on translating these parameters to 40L while preserving quality.
MeiraGTx (NASDAQ:MGTX), a clinical-stage genetic medicines company, reported significant progress across multiple programs in Q2 2025. The company achieved FDA alignment on its Phase 2 AQUAx2 study for radiation-induced xerostomia and received RMAT designation for AAV-GAD in Parkinson's disease treatment.
Key developments include plans to file for Marketing Authorization Approval with MHRA and BLA with FDA for LCA4 treatment in Q4 2025. The company's strategic collaboration with Hologen includes $200 million in cash consideration and formation of Hologen Neuro AI Ltd joint venture with up to $230 million additional funding.
Financial position shows $32.2 million in cash as of June 30, 2025, with additional receivables and expected proceeds sufficient to fund operations into 2027.